Amgen Patent-Cliff Exposure & CMS Drug Spending Portfolio

Amgen (Thousand Oaks, CA): 48 reconciled FDA prescription therapies (16.4% 2025 to 2030 cliff risk), $11.90B 2024 CMS Part D & Medicaid spend, and 192 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterThousand Oaks, CA
Reconciled FDA Portfolio Therapies48
2025 to 2030 Patent-Cliff Revenue Exposure16.4%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$11.90B
2024 Medicare Part D Spend$8.55B
2024 Medicaid Spend$3.34B
California HCAI SB 17 Filings192 WAC filings (max 31.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.